Welcome to our dedicated page for NewGenIvf Group SEC filings (Ticker: NIVF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NewGenIvf Group Limited (NIVF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. NewGenIvf files reports with the U.S. Securities and Exchange Commission primarily on Form 20-F and Form 6-K, detailing its evolving business across fertility services, technology licensing, digital assets, and real estate development.
Investors can review Form 6-K current reports that furnish unaudited interim financial results, describe changes to the company’s capital structure, and attach key press releases. Recent 6-Ks have covered multiple reverse stock splits, increases in authorized share capital, and updates on issued and outstanding shares. These filings explain how reverse splits affect the number of Class A ordinary shares and the adjustment of options, warrants, and convertible securities.
Other 6-K submissions include exhibits for announcements such as the share repurchase program, joint venture and joint development arrangements in Ras Al Khaimah, digital asset and tokenization agreements, and the non-binding term sheet for a proposed reverse merger with SAXA, Inc. Together, these documents outline NewGenIvf’s diversification into technology-driven fertility solutions, digital asset strategies, and UAE real estate projects.
On Stock Titan, each NIVF filing is paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand items like capital changes, financing agreements, and strategic transactions. Users can monitor new 6-Ks as they are posted to EDGAR, and refer to annual 20-F reports for a more comprehensive view of NewGenIvf’s business description, risk factors, and financial statements.
NewGenIVF Group Limited has agreed to an additional US$4 million investment in K25.ai, acquiring a further 4% equity stake in PredicXion Group Limited. The consideration includes US$1.9 million in cash or digital assets and 1,500,000 newly issued Class A ordinary shares, with a US$100,000 cash deposit paid at signing and the remaining cash due on or before September 30, 2026. Once this deal and prior investments close, NewGenIVF expects to own 10% of K25.ai, implying a US$100 million valuation based on the completed US$10 million Pre-A round. The share portion will be issued as restricted securities under Section 4(a)(2) and/or Regulation S exemptions from U.S. registration.
NewGenIVF Group Limited has entered into a Repurchase and Forbearance Agreement with a significant investor to buy back all outstanding convertible notes and warrants previously issued to that investor. In return, the investor agrees to forbear from converting the notes, exercising the warrants, or completing additional closings under earlier purchase agreements, as long as NewGen remains in compliance.
The repurchased notes and warrants will be cancelled once the agreed purchase prices are fully paid under an installment schedule extending through late 2027, which the company can prepay without penalty. NewGen expects this to remove a major source of potential equity dilution, simplify its capital structure, and improve clarity for shareholders as it pursues strategic initiatives, including digital asset treasury plans and potential expansion of its stake in K25.ai.
NewGenIvf Group Ltd filed an amended initial insider ownership report (Form 3/A) for Chief Financial Officer Chung Ho Fai. This amendment lists no insider transactions, exercises, gifts, tax withholdings, restructurings, or derivative positions in the data provided.
NewGenIvf Group Limited has expanded its Board by appointing four new independent directors. Ms. Lee Sze Mun joined as an independent director effective June 1, 2026, bringing over 22 years of experience in financial accounting, taxation, and group consolidation.
Mr. Lau Tsz Hin Vincent, Mr. Lam Chun Tung Patrick, and Mr. Cheung Kong Yiu were each appointed as independent directors effective June 8, 2026. The new directors contribute backgrounds in finance, risk management, digital assets, quantitative trading, and technology entrepreneurship, broadening the Board’s mix of skills and industry experience.
HRT FINANCIAL LP, a ten percent owner of NewGenIvf Group Ltd, reported an open-market sale of Common Stock. On June 4, 2026, it sold 64,945 shares at $0.781 per share. After this transaction, HRT FINANCIAL LP directly holds 18,134 shares of NewGenIvf common stock.
NewGenIvf Group Ltd insiders Wing Fung Alfred Siu and Hei Yue Tina Fong filed Amendment No. 1 to update their Schedule 13D on the company’s Class B ordinary shares. As of June 4, 2026, they beneficially own 113,771 Class B shares, representing 2.8% of that class.
On May 4, 2026, each was granted options to acquire 56,851 Class B shares under the 2024 Share Incentive Plan. They exercised all 56,851 options each on June 4, 2026 at an exercise price of US$0.0001 per share, and the company issued fully paid Class B shares to them. They state that they hold these shares to retain control and have amended their Joint Filing Agreement to continue reporting jointly.
NewGenIvf Group director Siu Wing Fung Alfred exercised vested stock options to acquire 56,851 Class B Ordinary Shares at $0.0001 per share on June 4, 2026. The exercise, under the 2024 Share Incentive Plan and an employee option agreement, raised his direct holdings to 56,881 shares after the transaction.
NewGenIvf Group Ltd director Fong Hei Yue Tina exercised stock options to acquire additional shares in the company. She exercised vested options to receive 56,851 Class B Ordinary Shares at an exercise price of $0.0001 per share under the issuer's 2024 Share Incentive Plan.
Following this option exercise, she directly holds 56,890 Class B Ordinary Shares. The options were granted under an employee share option agreement dated 4 May 2026, were accelerated by the independent directors on 26 May 2026, and were exercised on 4 June 2026. This is a compensation-related derivative exercise, not an open-market purchase or sale.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On June 2, it bought 23,018 shares at an average price of $0.944 per share. On June 3, it bought an additional 11,738 shares at an average price of $0.875 per share. After these transactions, HRT Financial LP directly holds 83,079 shares of NewGenIvf common stock.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On June 2, it bought 23,018 shares at an average price of $0.944 per share. On June 3, it bought an additional 11,738 shares at an average price of $0.875 per share. After these transactions, HRT Financial LP directly holds 83,079 shares of NewGenIvf common stock.
HRT Financial LP has filed an initial ownership report for NewGenIvf Group Ltd, indicating it is a ten percent owner of the company. The filing shows direct beneficial ownership of 71,341 shares of Common Stock as of the reported date, with no buys or sells disclosed in this report.
HRT Financial LP has filed an initial ownership report for NewGenIvf Group Ltd, indicating it is a ten percent owner of the company. The filing shows direct beneficial ownership of 71,341 shares of Common Stock as of the reported date, with no buys or sells disclosed in this report.